NX
NXTC.US NextCure Inc
- Market cap
- USD 30.6M
- P/E
- -
- P/B
- 5.33x
- ROE
- -764.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is NXTC.US undervalued?
Graham numberThe Graham number of NextCure Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NextCure Inc fundamental analysis
No fundamental analysis for NextCure Inc yet.
NextCure Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NextCure Inc
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of …
Full company profileNextCure Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
NextCure Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 0.00 | 0.00 | 6.35M | 22.4M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -582K | -1.68M | -27.9M | 22.4M | -4.30M | -4.48M | -3.68M | -2.87M | -2.19M | - |
| Operating Income | -15.5M | -23.2M | -37.5M | -41.2M | -70.8M | -75.9M | -67.6M | -59.7M | -57.6M | -42.8M |
| EBITDA | -15.0M | -21.1M | -34.8M | -37.8M | -65.1M | -71.8M | -59.0M | -54.3M | -53.7M | -41.3M |
| Net Income | -15.5M | -22.8M | -33.7M | -33.2M | -69.4M | -69.4M | -62.7M | -55.7M | -55.8M | -42.0M |
| EPS | -8.17 | -12 | -26 | -14 | -30 | -30 | -27 | -24 | -20 | -7.92 |
| Balance Sheet | ||||||||||
| Total Assets | 19.5M | 148M | 356M | 307M | 242M | 184M | 128M | 80.9M | 50.2M | 9.70M |
| Total Liabilities | 43.9M | 195M | 34.7M | 12.9M | 9.00M | 16.6M | 13.6M | 15.4M | 15.2M | 4.20M |
| Shareholders' Equity | -24.4M | -46.9M | 321M | 294M | 233M | 168M | 114M | 65.5M | 34.9M | 5.50M |
| Cash & Short-term Investments | 8.43M | 135M | 335M | 283M | 220M | 160M | 108M | 68.6M | 41.8M | 8.73M |
| Total Debt | 964K | 587K | 5.14M | 3.47M | - | 7.12M | 6.61M | 5.95M | 5.15M | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -12.5M | 7.99M | -35.6M | -45.0M | -57.2M | -53.9M | -53.0M | -40.8M | -49.6M | -46.9M |
| Capital Expenditure | 8.65M | 3.06M | 3.37M | 7.13M | 2.36M | 2.12M | 820K | 474K | 0.00 | 0.00 |
| Free Cash Flow | -21.2M | 4.93M | -39.0M | -52.1M | -59.6M | -56.0M | -53.8M | -41.3M | -49.6M | -46.9M |
| Ratios | ||||||||||
| ROE | - | - | -10.5% | -11.3% | -29.7% | -41.4% | -54.8% | -85.0% | -159.8% | -764.0% |
| ROA | -79.5% | -15.4% | -9.5% | -10.8% | -28.6% | -37.7% | -49.0% | -68.8% | -111.3% | -433.5% |
| Net Profit Margin | - | - | -531.5% | -148.3% | - | - | - | - | - | - |
| Debt to Equity | - | - | 0.02x | 0.01x | - | 0.04x | 0.06x | 0.09x | 0.15x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
NextCure Inc dividends
NextCure Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:12 on Jul 14, 2025.
Who owns NextCure Inc
- Insiders 18.80%
- Institutions 61.40%
- Public & others 19.80%
- Shares outstanding 4.58M
- Free float 2.27M
Top funds holding NXTC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 123K | 2.69% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 50.0K | 1.09% | 0.00% | Aug 2026 |
| Abante Quant Value FI | 20.2K | 0.44% | 0.00% | Aug 2026 |
| Fidelity Extended Market Index | 19.8K | 0.43% | -0.38% | Sep 2026 |
| Nomura Healthcare Fund Class I | 12.5K | 0.27% | 0.00% | Sep 2026 |
| iShares Micro-Cap ETF | 10.9K | 0.24% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 4.00K | 0.09% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 3.63K | 0.08% | 0.00% | Sep 2026 |
| DFA US Micro Cap I | 2.71K | 0.06% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 741.00 | 0.02% | 0.00% | Sep 2026 |
| BlackRock Diversified Equity Alpha Inst | 689.00 | 0.02% | 0.00% | Jul 2026 |
| Dimensional US Core Equity 2 ETF | 59.00 | 0.00% | 0.00% | Oct 2026 |
Top institutions holding NXTC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Ikarian Capital, LLC | 288K | 6.30% | +20.98% | Jun 2026 |
| Adage Capital Partners Gp LLC | 277K | 6.06% | 0.00% | Jun 2026 |
| Sofinnova Ventures | 223K | 4.86% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 157K | 3.43% | -2.26% | Jun 2026 |
| Millennium Management LLC | 88.1K | 1.93% | 0.00% | Jun 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 84.7K | 1.85% | +21.65% | Jun 2026 |
| Squadron Capital Management LLC | 64.5K | 1.41% | -75.67% | Jun 2026 |
| Verdad Advisers, LP | 60.5K | 1.32% | +40.73% | Jun 2026 |
| Pfizer Inc | 44.4K | 0.97% | +0.02% | Sep 2026 |
| Affinity Asset Advisors, LLC | 42.0K | 0.92% | -82.65% | Jun 2026 |
| Renaissance Technologies Corp | 39.1K | 0.86% | -77.13% | Sep 2026 |
| BlackRock Inc | 37.3K | 0.82% | +34.38% | Jun 2026 |
| HRT FINANCIAL LLC | 36.5K | 0.80% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 32.7K | 0.71% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 29.9K | 0.65% | -3.82% | Jun 2026 |
| CARDIFF PARK ADVISORS, LLC | 21.8K | 0.48% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 16.1K | 0.35% | +0.74% | Jun 2026 |
| Delaware Management Holdings Inc | 12.5K | 0.27% | 0.00% | Jun 2026 |
| Virtu Financial LLC | 11.0K | 0.24% | 0.00% | Jun 2026 |
| Acadian Asset Management LLC | 10.7K | 0.23% | -43.82% | Sep 2026 |
NextCure Inc company profile
- Company name
- NextCure Inc
- Ticker
- NXTC.US
- Exchange
- USA Stocks
- Listed since
- May 9, 2019
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 40
- Fiscal year end
- December
- Address
- 2850 Quarry Lake Drive, Baltimore, MD, United States, 21209
- Phone
- 240 399 4900
- Website
- nextcure.com
About NextCure Inc
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Baltimore, Maryland.
NextCure Inc management
7- Mr. Michael S. Richman MSBACo-Founder, CEO, President & Director · born 1961
- Dr. Timothy Mayer Ph.D.Chief Operating Officer · born 1965
- Dr. Lieping Chen M.D., Ph.D.Co-Founder & Chairman of Scientific Advisory Board · born 1957
- Mr. Steven P. Cobourn CPAChief Financial Officer · born 1963
- Mr. Kevin G. ShawSenior VP & General Counsel · born 1974
- Mr. Sourav Kundu Ph.D.Senior Vice President of Development & Manufacturing · born 1960
- Dr. Sebastien Maloveste Ph.D.Senior Vice President of Business Development